In a randomized trial, MK-677 failed to slow Alzheimer's disease progression despite successfully elevating GH and IGF-1 — restoring the GH axis alone isn't sufficient to treat established AD.
Key findingMK-677 successfully increased GH/IGF-1 in AD patients but showed no clinical benefit on cognitive decline, ADAS-cog, or CDR-sb over the trial period —
What the researchers found
MK-677 successfully increased GH/IGF-1 in AD patients but showed no clinical benefit on cognitive decline, ADAS-cog, or CDR-sb over the trial period — proving GH axis restoration alone is insufficient for treating established Alzheimer's disease.
Why it matters
Relevant for mk-677, neuroprotection, hormone-optimization.
How the study worked
RCT study.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Neurology, 71(21), 1702-8
Citation
Sevigny, J J; Ryan, J M; van Dyck, C H; Peng, Y; Lines, C R; Nessly, M L. (2008). Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.. Neurology, 71(21), 1702-8. https://doi.org/10.1212/01.wnl.0000335163.88054.e7